P01AI165072

Discovering Durable Pan-Coronavirus Immunity - Overall Summary

Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2 is a devastating human threat. While successful vaccine programs are underway, genetic drift and immune escape have already begun to subvert immunity, with more variants likely to continue to emerge. Moreover, the rates of zoonotic CoV transmission have increased over the past two decades—indicating that it may not be long before another CoV breaches host-species barriers into humans.

Next-generation vaccine design strategies that are able to provide robust protection against evolving SARS-CoV-2 strains in addition to other CoVs are urgently needed. The overall goal of this program is to produce critical information necessary for the design and testing of next-generation vaccine strategies that provide protective efficacy with the greatest possible breadth across the CoV family.

The overall program hypothesis is that immunological discernment of heterogeneity in human responses to SARS-CoV-2 infection and vaccination will illuminate factors that can impact efficacy and breadth of CoV vaccine strategies. This hypothesis is supported by recent publications and preliminary data from our team.

In this regard, although hundreds of vaccines are under development, the targets most relevant for pan-CoV immunity may defy the simple need for the induction of neutralizing antibody responses, which largely bind to non-conserved areas in the S1 region of the viral spike (S) protein—susceptible to viral escape. Emerging evidence from our team points to the importance of the S2 region, which is more conserved across CoVs. Our team has found that rapid induction of anti-S2 antibodies is connected to less death in severe disease, more cross-reactive memory B cell responses, swift healing in mild disease, and improved antibody durability after disease resolution. The factors underlying why some people develop better clinical outcome-associated crossreactive anti-S2 immune responses remains to be fully defined.

We have assembled a multidisciplinary team with expertise in immunology, virology, genetics, medicine, biochemistry, structural biology, and mathematics to achieve the overall program goal. The complementary and integrative expertise of the team will come together to:

1) Finely map the humoral and cellular responses to SARS-CoV-2 variants and coronaviral relatives that emerge after natural infection or vaccination,
2) Define the mechanism(s) by which these responses confer protection, and
3) Utilize these mechanistic correlates of immunity to inspire cutting-edge, structurally stable native-like S antigens that will be used in a step-wise improvement approach in vaccination and protection studies.

Collectively, the data generated by this team will:
(A) Identify immunological correlates of anti-CoV breadth expected to inform vaccine design;
(B) Define the most conserved targets on CoV S accessible to the human adaptive immune system and mechanistic insights into their recognition;
(C) Generate novel immunogens incorporating B and T cell strategies informed by (A-C) above; and
(D) Test them in the context of program-optimized delivery methods to maximize breadth of protective, durable CoV immunity.

Brigham & Womens Hospital

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Massachusetts United States

State-Wide

NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) (PAR-20-072)

Amendment Since initial award the End Date has been extended from 08/31/24 to 08/31/25 and the total obligations have increased 66% from $11,809,995 to $19,638,315.